Confession: Open-minded medicine must still be evidence-based medicine.

Did the FDA just approve BPC-157 and other popular peptides? Not exactly and that distinction matters.

Following a closely watched FDA advisory committee meeting, headlines and social media posts began suggesting that peptides such as BPC-157, TB-500, KPV, MOTS-c, Epitalon, and Semax had been "approved" or "unbanned."

Let's be clear: An advisory committee recommendation is not the same thing as FDA approval, proven effectiveness, or established long-term safety.

In this episode of Confessions of a Male Gynecologist, Americas Holistic Gynecologist, Dr. Shawn Tassone explains what the recent FDA peptide vote actually means, what could happen next, and why patients and practitioners should be careful about confusing expanded compounding access with scientific validation.

Peptides are increasingly promoted online for injury recovery, inflammation, gut health, mitochondrial function, metabolism, sleep, longevity, cognitive performance, this list goes on...

Some have interesting biological mechanisms and promising preliminary research, but many of the claims being made online extend far beyond the available human evidence.

In this episode Dr. Tassone examines:

• BPC-157: Why its reputation as a powerful healing peptide has grown faster than the quality of the human research.

• KPV: Its proposed anti-inflammatory benefits and the lack of meaningful clinical studies in humans.

• TB-500: Why it is frequently confused with thymosin beta-4 and why the distinction matters when evaluating research.

• MOTS-c: The growing interest in its potential mitochondrial and metabolic effects and the questions that remain unanswered.

• Epitalon: Claims involving sleep, longevity, and anti-aging versus the strength of the available evidence.

• Semax: Why having more reported human exposure does not automatically mean the research meets modern clinical standards.

• The FDA's 503A Bulk List: What pharmacy compounding access means and what it does not mean.

• Peptide Marketing: How experimental therapies can begin sounding proven long before adequate safety and effectiveness data exist.

Promising mechanisms deserve research, patient experiences can help generate better questions, but neither should be used as a replacement for rigorous human trials, reliable manufacturing standards, appropriate medical oversight, and honest conversations about uncertainty.

Before assuming that a favorable committee vote means a peptide is now FDA approved, safe, or clinically proven, listen to this episode for the full context, share this episode with someone considering peptide therapy, and leave a rating or review to help more people find evidence-based conversations about their health and hormones!

Episode Resources:

Work with Dr. Tassone | Tassone Advanced Gynecology

Please contact the clinic directly at (512) 956- 0296 with all scheduling inquiries.

Purchase Dr. Tassone's Best-Selling Book | The Hormone Balance Bible

Dr. Tassone's Integrative Hormonal Archetype Quiz | Discover Your Hormonal Archetype

Medical Disclaimer
This podcast and website represent the opinions of Dr. Shawn Tassone and his guests. The content here should not be taken as medical advice and is for informational purposes only. Because each person is so unique, please consult your health care professional for any medical questions.